Drug Trial Radar · NCT06407947
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jun 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 6, 2024
Primary completion
Jun 3, 2027
Study completion Jun 3, 2027
Sponsor
- Lead sponsor
- Shanghai Changzheng HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- CARsgen Therapeutics Co., Ltd.
- First posted
- May 9, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
Chimeric antigen receptor modified T cells InfusionDrug
chimeric antigen receptor T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AE) after CT071 infusionTime frame: From first dose of study drug administration to end of treatment (up to 24 months)
- Overall response rate (ORR)Time frame: From first dose of study drug administration to end of treatment (up to 24 months)
- Recommended Phase II Dose of CT071 in patients with high-risk newly diagnosed multiple myelomaTime frame: Assessed from the date of first dose of study treatment until 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Juan Du
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.